Neuromyelitis optica spectrum disorder: do patients positive and negative for anti¿aquaporin-4 antibodies present distinct entities? A Colombian perspective P.A. Ortiz Salas; M. Gaviria Carrillo; G.A. Cortés Bernal; K. Moreno Medina; L.F. Roa; J.H. Rodríguez Quintana;

Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab? R. Sawaya; G. Saab; H. Moussa;

The prevalence, incidence, and clinical assessment of neuromyelitis optica spectrum disorder in patients with demyelinating diseases M.A. Mireles-Ramírez; I.E. Velázquez-Brizuela; N. Sánchez-Rosales; Y. Márquez-Pedroza; M.R. Hernandez-Preciado; G. Gabriel Ortiz;